Glucocorticoids remain among the most important drugs in the treatment of acute lymphoblastic leukemia (ALL).
Recent progress in combination chemotherapy for ALL has resulted in a high remission rate, reaching 60-80% in many multi-institutional trials. [1] [2] [3] However, the cure rates in most trials still remain low at 20-40%.
3) The non-curable cases are associated with the emergence of resistant clones of malignant cells.
Treatment of ALL has included glucocorticoids for almost 50 years. 1, 2, 4) Although 70-90% of ALL primarily respond to single use of glucocorticoids, many cases become resistant to glucocorticoids at relapse. 1) Moreover, PSL resistance is significantly higher in adults than in childhood. 5) Recently, glucocorticoids have been the subject of renewed interest. In vitro and in vivo responses of leukemic cells to glucocorticoids have highly predictive outcomes. 6) Kaspers et al. reported that in vitro resistance to PSL was significantly related to the short-term and long-term clinical response to chemotherapy 7) and in vitro resistance to PSL was related to the probability of diseasefree survival after combination chemotherapy. 8) Given this, glucocorticoids still remain among the key drugs, as do vinca alkaloids and anthracyclines.
However, the mechanisms of resistance to glucocorticoids have not yet been precisely clarified, though several studies have been reported. Glucocorticoid resistance is most commonly linked to altered receptor number or function. Low expression of GRs was associated with a poor response to glucocorticoid-based therapies and a higher risk of relapse. 9, 10) As Pgp has been shown to transport DEX in experimental cell lines, increased expression of Pgp may be important for glucocorticoid resistance.
11) It has also been reported that overexpression of Bcl-2 is related to resistance to glucocorticoid-induced apoptosis. 12, 13) An earlier study by Miyashita and Reed using 697/Bcl-2, which is a stable transfectant with a recombinant Bcl-2-containing retrovirus, 14) demonstrated that high levels of Bcl-2 protein protected human pre-B 697 cells from the acute cytotoxic effects of DEX. However, it remains unclear whether Bcl-2 also has a central role in the mechanism of DEX resistance in acquired-resistant cell lines. In addition, the mechanisms of glucocorticoid resistance have been studied in vitro in some T-cell leukemic cell lines, such as CEM. 15, 16) However, less work has been done with resistant B-cell leukemic cell lines. 13, 14) In this study, we established a DEX-resistant human pre-B lineage leukemia cell line (697/DEX) from human pre-B lineage leukemia cells (697/Neo) and investigated the mechanism of resistance. We also investigated the difference of drug resistance mechanisms between the acquired DEX-resistant cell line and the Bcl-2-transfected cell line (697/Bcl-2). The possibility of elevation of the GSH redox pathway, which has received attention as a mechanism of clinical resistance in leukemia 17) and of relatively poor prognosis in ALL, 18) was also investigated.
MATERIALS AND METHODS
Cell lines 697/Neo and 697/Bcl-2 cell lines were established from a human pre-B leukemia cell line derived from child ALL. 14) These cells are infected with control retrovirus (697/Neo) and recombinant Bcl-2 retrovirus (697/ Bcl-2), respectively.
14) The DEX-resistant cell line was obtained by exposure of 697/Neo to stepwise increasing concentrations (from 1 nM to 1 µM) of DEX. When its doubling time in the presence of 1 µM DEX was similar to that of parental 697/Neo in the absence of DEX, the cells were cloned by the limiting dilution method. The established 697/DEX was more than 430-fold resistant to DEX. 697/Neo, 697/Bcl-2 and 697/DEX were maintained by serial culture in RPMI-1640 medium (Nissui, Tokyo) containing 10% fetal bovine serum (FBS; Gibco BRL, Life Technologies, Rockville, MD) and kanamycin (Meiji Seika Co., Tokyo) at 37°C in humidified air with 5% CO 2 21) with the Pgp monoclonal antibody PE-UIC2. MRP was analyzed by the method of Flens et al. 22) with the MRP monoclonal antibody m6 using a Becton Dickinson FACScan (FACS Caliber). As a negative control, we used the mouse IgG in place of MoAb. DEX uptake and efflux assay The amounts of DEX accumulated by 697/Neo and 697/DEX were evaluated using [
3 H]DEX. Briefly, an aliquot of 2×10 6 cells were incubated with 1 µM of [ 3 H]DEX with or without 10 µg/ ml verapamil at 37°C for 90 min. After washing, scintillation liquid was added to the cell pellet, and the radioactivity was determined with a scintillation counter. Rhodamine 123 efflux assay was performed by the method of Webb et al. 23) Briefly, 5×10 5 resistant cells were incubated with 100 ng/ml of Rhodamine 123 with or without 10 µg/ml verapamil, an inhibitor of Pgp, for 30 min at 37°C. The cells were washed twice in PBS, resuspended in RPMI and efflux was allowed to proceed for 3 h at 37°C. The cells were then washed twice and analyzed on a Becton Dickinson FACScan (FACS Caliber). Calcein efflux assay was performed by using the method of Feller et al. with some modification. 24, 25) Briefly, 1×10 6 cells were incubated with 0.5 µM calcein-AM with or without 2 mM probenecid, an inhibitor of MRP, for 15 min at 37°C. After centrifugation, cells were resuspended in fresh medium, and the efflux of calcein was allowed to proceed for 90 min at 37°C. Intracellular calcein accumulation was determined by measuring calcein fluorescence through a 530 nm bandpass filter with excitation at 488 nm using a Becton Dickinson FACScan (FACS Caliber). GR determination The number of specific GR was determined in terms of the binding of [ 3 H]DEX using a whole-cell assay 26) with 5 different concentrations (1-50 nM) of [ 3 H]DEX in the presence (1-50 µM, respectively) and absence of unlabeled DEX at 37°C for 90 min. Specific binding was calculated as the number of binding sites per cell from the difference between the total and non-specific binding according to the method of Scatchard.
27)
GSH measurement Total intracellular GSH content was measured by the Tietze method, as previously described, with minor modifications. 28) Briefly, 5×10 6 cells were prepared, washed 2 times with ice-cold PBS, and suspended in 125 mM sodium phosphate buffer containing 6.3 mM EDTA, pH 7.5 (sodium phosphate buffer). The cells were lysed by sonicating four times at 130 W for 10 s at 4°C. Then 12% 5-sulfosalicylic acid was added to the lysates, and precipitation was allowed to occur for 2 h at 4°C. After centrifugation at 10 000g for 15 min, protein-free lysates were obtained. The reaction mixture for determination of the GSH content consisted of the lysates, 0.3 mM NADPH, 6 mM 5,5′-dithiobis-(2-nitrobenzoic acid), and 0.5 units of GSH reductase. The absorbance at 412 nm was monitored for 6 min using a plate reader (SPECTRA Max250) (Molecular Devices Co., Sunnyvale, CA). The GSH content was calculated from the change in the rate of absorbance on the basis of a standard curve. GSH depletion assay GSH depletion was achieved by 24 h preincubation of the cells in RPMI-1640 supplemented with 15 µM BSO. 29) Then, the cytotoxicity was determined after 72 h incubation with various concentrations of DEX. The IC 50 was determined by the Trypan blue dye exclusion method. Caspase-3/7 enzyme activity For the detection of caspase-3/7 activity, we used Dimmeler's method. 30) Briefly, 1×10 6 cells were lysed in buffer (1% Triton X-100, 0.32 M sucrose, 5 mM EDTA, 1 mM PMSF, 1 µg/ml aprotinin, 1 µg/ml leupeptin, 2 mM DTT, 10 mM Tris/ HCl, pH 8) for 15 min at 4°C, followed by centrifugation (20 000g, 2 min). The caspase-3/7 activity was detected by measuring the fluorogenic MCA liberated from the caspase-3-like substrate, Ac-DEVD-MCA, in assay buffer (100 mM Hepes, 10% sucrose, 0.1% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), pH 7.5, 1 mM PMSF, 1 µg/ml aprotinin, 1 µg/ml leupeptin, 2 mM DTT) using an excitation wavelength of 380 nm and an emission wavelength of 460 nm. To confirm the inhibition of caspase-3/7, a control reaction was performed by incubating an induced sample with a caspase-3 family protease inhibitor, Ac-DEVD-CHO, before addition of the Ac-DEVD-MCA. Statistical analysis Values are expressed as means±SD. Statistical differences were evaluated by using Student's t test, as for GR and GSH. P<0.05 was considered significant.
RESULTS

Establishment of DEX-resistant cell line and its crossresistance to other antileukemia drugs
The IC 50 values of 697/Neo, 697/DEX and 697/Bcl-2 to DEX were 23.3±5.7 nM, more than 10 µM, and more than 10 µM, respectively. Both 697/DEX and 697/Bcl-2 were over 430-fold more resistant to DEX than 697/Neo. A colonyforming assay with 697/DEX and 697/Bcl-2 also revealed over 400-fold resistance to DEX. The cytotoxicities of other antileukemic drugs to 697/DEX were compared with those to 697/Neo following incubation for 72 h in the presence of each drug. 697/DEX was over 140-fold more resistant to PSL, but showed weak resistance to DNR (2.4-fold) and no cross-resistance to VCR, PTX, VP-16 or MTX (Table I) . A colony-forming assay in 697/DEX also revealed a 2.8-fold resistance to DNR. The expression of Bcl-2 protein in 697/DEX To determine the expression of the Bcl-2 protein in 697/DEX compared with 697/Bcl-2 cells, we performed immunofluorescence analysis by flow cytometry. The expression of the Bcl-2 protein was at substantially the same level in 697/DEX as in 697/Neo (Fig. 1) . The MFI of 697/Neo, (Fig. 2) . Interestingly, the Pgp efflux pump in 697/DEX did not work in Rhodamine 123 efflux assay using verapamil as a Pgp modulator (Fig. 3) , suggesting that 697/DEX has a non-functional mutant of Pgp on its membrane. MRP was not expressed in 697/DEX by direct immunofluorescence assay (Fig. 4A) , and also did not work in calcein efflux assay using probenecid as an MRP modulator (Fig. 4B) . GR determination The roles of the GRs were evaluated in these cell lines. Radioligand binding studies were performed to determine the density of the binding sites of 697/Neo, 697/DEX and 697/Bcl-2. The binding site numbers of 697/Neo and 697/DEX amounted to 11 050±437 and 3390±786 sites per cell, respectively (P=0.0001). These results showed that the GRs in 697/DEX were 3-fold lower than those in 697/Neo. In addition, the binding site numbers of 697/Bcl-2 were also significantly reduced to 6280±830 sites per cell (P=0.001).
Measurement of GSH and depletion by BSO
In an attempt to define further the mechanisms of resistance, we investigated whether the amount of anti-oxidative substances increased to enhance the redox state of 697/DEX. We measured the intracellular levels of total GSH. The GSH contents of 697/Neo, 697/DEX and 697/Bcl-2 were 241.8±31. 4 6 ) per sample were resuspended in 2% paraformaldehyde in PBS. After 10 min on ice, 1% Triton X-100 was added, and 10 min later the cells were washed twice in cold PBS. Indirect immunofluorescence assay was then carried out using antiBcl-2 MoAb (clone 124). FITC-conjugated goat antimouse MoAb was added for 30 min at 4°C. The cells were analyzed using a FACScan flow cytometer. The x axis shows log fluorescence intensity and the y axis shows relative cell number. negative control, 697/Neo, 697/DEX, 697/Bcl-2. protein, respectively. 697/DEX and 697/Bcl-2 showed reproducibly higher levels of GSH than the parental 697/ Neo (P=0.005, P=0.016, respectively vs. 697/Neo). These data suggested that the GSH redox cycle was more active in 697/DEX and 697/Bcl-2 than in 697/Neo. On addition of BSO, both 697/DEX and 697/Bcl-2 recovered sensitivity to DEX (Fig. 5) . We have previously confirmed that GSH depletion was achieved by 24 h preincubation of the cells in RPMI-1640 supplemented with 15 µM BSO. Caspase-3/7 enzyme activity Apoptotic cell death is usually known to be associated with activation of cysteine proteases, mainly caspase-3. As shown in Fig. 6A , the caspase-3/7 activity with BSO and DEX treatment was increased 6-fold compared with BSO treatment at 24 h of culture in 697/Neo. However, the activation of caspase-3/7 was not detected in 697/DEX or 697/Bcl-2. Preincubation with the caspase-3 family protease inhibitor, Ac-DEVD-MCA, had no effect. With BSO treatment, both 697/DEX and 697/Bcl-2 recovered sensitivity to DEX, but caspase-3/7 was not activated during 24 h of culture (Fig. 6A) . Furthermore, we also did not detect the activation of caspase-3/7 during 48 h culture with BSO and DEX treatment in 697/DEX and 697/Bcl-2 (Fig. 6B) .
DISCUSSION
In this study, we established a DEX-resistant cell line, 697/DEX. This cell line showed no cross-resistance to other anti-leukemic drugs including vinca alkaloids, except for weak resistance to DNR (2.4-fold). Since the mechanisms of glucocorticoid resistance have been mainly studied with T-cell leukemia cell lines, such as CEM-C1 in vitro so far, 17, 18) our cell line should be useful for studies on the glucocorticoid resistance mechanism of B-cell leukemia cell lines.
Prolonged survival of B-lineage ALL cells is accompanied by the expression of the Bcl-2 protein. 13, 31) It has been shown that Bcl-2 protects cancer cells from apoptosis induced by a variety of anticancer drugs, 14) although the precise mechanism of the Bcl-2-induced multidrug resistance is unknown. High levels of the Bcl-2 protein have been shown to protect 697 cells from the acute cytotoxic effects of DEX, using Bcl-2-virus-infected cells. 14) Our results demonstrated that the expression of Bcl-2 was not up-regulated at the protein level in 697/DEX compared with 697/Neo (Fig. 1) . The results were the same using western blotting analysis (data not shown). These findings suggest that the level of Bcl-2 did not play an important role in the resistance to DEX in 697/DEX, different from the artificial Bcl-2-virus-transfected cell line, 697/Bcl-2.
Increased expression of Pgp has been recognized as the most consistent change in multidrug resistance. 32) Human Pgp has been shown to transport DEX in an experimental cell line. 11) Our results showed that the Pgp in 697/DEX is expressed on the membrane (Fig. 2) . Interestingly, the Pgp efflux pump in 697/DEX did not work in [ were incubated with 0.5 µM calcein-AM with or without 2 mM probenecid for 15 min at 37°C. After centrifugation, cells were resuspended in fresh medium, and the efflux of calcein was followed for 90 min at 37°C. Intracellular calcein accumulation was measured in terms of the absorbance through a 530 nm bandpass filter with excitation at 488 nm using a FACscan (Becton Dickinson). Thin solid line, without probenecid; thick solid line, with probenecid. in augmenting cell survival and is associated with the modulation of a sphingomyelin-ceramide apoptotic pathway.
33) It remains possible that among the Pgp-positive resistant cells in the presence of lower concentrations of DEX, another mutation affords cells with potent resistance via another mechanism, but with loss of Pgp function. The mechanisms of the non-efflux function in 697/DEX are still under investigation in our laboratory.
Previous studies have shown that glucocorticoid-resistance is most commonly linked to altered receptor number or function. 10) In contrast, Nicklas et al. indicated that resistance to glucocorticoids in vivo is not due to an alteration of the GR. 34) Our results showed that the numbers of GR in 697/DEX and 697/Bcl-2 were fewer than those in 697/Neo. Although 697/DEX may decrease the number of down-regulated GR on exposure to DEX, the number of receptors in the 697/Bcl-2 cells was also decreased without exposure to DEX. Miyashita et al. reported that the S49.1 and WEHI7.2 murine T-lymphoid cell lines infected with a recombinant retrovirus encoding human Bcl-2 had a marked resistance to DEX-mediated cell death and apoptosis without lowering of the GR level. 35) On the other hand, Bcl-2 has recently been demonstrated to regulate the expression of hormone receptors, such as estrogen recep- tor, in breast carcinoma cells. 36) Bcl-2 may decrease the GR numbers. Since the correlation between sensitivity to glucocorticoids and the GR number is still controversial, further study is needed.
Recently, it has been noted that elevation of GSH in the GSH redox pathway is associated with acquired drug resistance. 29) For example, GSH levels in ALL on relapse were more than 2-fold higher than those at onset. 17) In the present study, we showed that 697/DEX and 697/Bcl-2 had higher levels of GSH than the parental 697/Neo. Moreover, we showed that BSO treatment, which is a specific inhibitor of GSH synthesis, could restore susceptibility to DEX in 697/DEX (Fig. 5) . These results suggest that the intracellular GSH level is one of the important factors determining DEX resistance. As one possible mechanism, GSH can combine with anticancer drugs to form less toxic and more water-soluble GSH conjugates. The GSH conjugates of anticancer drugs can be exported from the cells by MRP and the glutathione-S conjugate export pump (GS-X pump).
37) However, we could not detect MRP expression and function in 697/DEX (Fig. 4) . Iwata et al. reported that GSH plays crucial roles in the regulation of lymphocyte proliferation. Under GSHdepleted conditions, the inability to neutralize oxidative stress results in lymphoid cell death. 38) We speculate that the elevation of GSH in 697/DEX maintains the intracellular redox balance against oxidative stress induced by DEX. Further studies are required to elucidate the activity of enzymes responsible for GSH redox homeostasis, such as glutathione synthase, glutathione reductase and glutathione peroxidase.
Next, we investigated whether the apoptotic signal pathway with the depletion of GSH was associated with the caspase-3/7 activation in these cell lines. Our results showed that caspase-3/7 was activated during apoptosis in 697/Neo under depletion of GSH with DEX treatment for 24 h. However, in 697/DEX and 697/Bcl-2, caspase-3/7 was not activated under the same conditions (Fig. 6A) . Even with 48 h incubation, we could not detect the activation of caspase-3/7, although the cell growth was already suppressed (Fig. 6B) . We also could not detect the activation of caspase-6 during 48 h incubation of 697/DEX and 697/Bcl-2 (data not shown). Our study suggested that the cell death mechanisms of 697/DEX and 697/Bcl-2 by GSH-depletion were different from that of 697/Neo. When 697/DEX was cultured in BSO and DEX for 48 h, we found 60% of the intracellular nuclei to be positive by propidium iodide staining. Iwata et al. reported that the lymphoid cells died by an apoptotic mechanism under GSH-depleted conditions. 38) We speculate that 697/DEX and 697/Bcl-2 might die through caspase-independent programmed cell death or the necrotic pathway.
In conclusion, DEX-resistance in 697/DEX is associated not only with GR reduction but also raised intracellular GSH levels. This is the first report to show that elevation of GSH plays an important role in the acquired DEX-resistance of B-cell lines. In the clinical field, measurement of GSH may be useful to predict DEX-resistance. In addition, the fact that DEX-resistance may be reversed with BSO may offer strategies for overcoming resistance to glucocorticoids in B-cell lineage ALL.
